Thiogenesis Therapeutics, Corp. (TSXV: TTI)

Thiogenesis Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4.15	7.08	6.2	0.06	0.02
Cash & Short-Term Investments	4.15	7.08	6.2	0.06	0.02
Cash Growth	14.19%	14.21%	9805.77%	315.03%	-
Other Receivables	0.07	0.09	0.06	0.17	0
Receivables	0.07	0.09	0.06	0.17	0
Prepaid Expenses	0.03	0.08	0.04	-	0.03
Total Current Assets	4.25	7.24	6.29	0.23	0.04
Total Assets	4.25	7.24	6.29	0.23	0.04
Accounts Payable	0.11	1.67	0.31	0.68	0.03
Accrued Expenses	-	0.04	-	0	0
Short-Term Debt	-	-	-	0.46	0.25
Other Current Liabilities	-	-	-	0.15	-
Total Current Liabilities	0.11	1.71	0.31	1.29	0.28
Total Liabilities	0.11	1.71	0.31	1.29	0.28
Common Stock	15.67	15.01	11.13	1.05	0
Additional Paid-In Capital	-	-	-	0.04	0.49
Retained Earnings	-13.16	-11.14	-6.18	-2.14	-0.73
Comprehensive Income & Other	1.63	1.66	1.03	-0.01	-0
Shareholders' Equity	4.15	5.53	5.98	-1.06	-0.24
Total Liabilities & Equity	4.25	7.24	6.29	0.23	0.04
Total Debt	-	-	-	0.46	0.25
Net Cash (Debt)	4.15	7.08	6.2	-0.4	-0.24
Net Cash Growth	14.19%	14.21%	-	-	-
Net Cash Per Share	0.09	0.18	0.24	-0.03	-0.02
Filing Date Shares Outstanding	45.51	44.57	38.86	12	10
Total Common Shares Outstanding	45.51	44.57	38.86	12	10
Working Capital	4.15	5.53	5.98	-1.06	-0.24
Book Value Per Share	0.09	0.12	0.15	-0.09	-0.02
Tangible Book Value	4.15	5.53	5.98	-1.06	-0.24
Tangible Book Value Per Share	0.09	0.12	0.15	-0.09	-0.02

Source: S&P Capital IQ. Standard template. Financial Sources.